Wednesday, June 20, 2018

Eidos Therapeutics Prices IPO, To Debut Today

San Francisco-based Eidos Therapeutics, a clinical stage biopharaceuticals firm focused on diseases caused by transthyretin (TTR) amyloidosis (ATTR), priced its IPO last night, saying it will sell 6,250,000 shares of its common stock at $17.00 per share. The company will start trading this morning on the Nasdaq Global Select Market as EIDX. The IPO was underwritten by J.P. Morgan, BofA Merrill Lynch, and Barclays. Eidos Therapeutics was majority owned by BridgeBio Pharma.